Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$3.21
0.041.26%
At close: Dec 16, 4:00 PM EST
$3.23
0.020.62%
After Hours: 4:31 PM EST
Comments
Loading...
Aclaris Therapeutics (ACRS) Stock Price, Quote, News & History
ACRSNASDAQ
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Aclaris Therapeutics (ACRS) stock?
You can purchase shares of Aclaris Therapeutics (NASDAQ:ACRS) through any online brokerage.
Who are Aclaris Therapeutics (ACRS) competitors?
Other companies in Aclaris Therapeutics’s space includes: Atea Pharmaceuticals Inc (NASDAQ:AVIR), MediWound Ltd (NASDAQ:MDWD), Zevra Therapeutics Inc (NASDAQ:ZVRA), SNDL Inc (NASDAQ:SNDL) and Bioage Labs Inc (NASDAQ:BIOA).
What is the forecast, or price target, for Aclaris Therapeutics (ACRS) stock?
Aclaris Therapeutics has a consensus price target of $10.73.
What is the current price for Aclaris Therapeutics (ACRS)?
The stock price for Aclaris Therapeutics (NASDAQ: ACRS) is $3.23 last updated December 16, 2025 at 4:31 PM EST.
Does Aclaris Therapeutics (ACRS) pay a dividend?
There are no upcoming dividends for Aclaris Therapeutics.
When is Aclaris Therapeutics (NASDAQ:ACRS) reporting earnings?
Aclaris Therapeutics does not have any upcoming earnings scheduled.
Is Aclaris Therapeutics (ACRS) going to split?
There is no upcoming split for Aclaris Therapeutics.
What sector and industry does Aclaris Therapeutics (ACRS) operate in?
Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
